Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Por Tremblay, Gabriel, Dolph, Mike, Patel, Sachin, Brandt, Patricia, Forsythe, Anna
Publicado no Cost Eff Resour Alloc (2018)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Por Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio
Publicado no Cancer Manag Res (2018)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

Por Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Elliott, Brian, Briggs, Andrew
Publicado no Clinicoecon Outcomes Res (2018)

Systematic review of health state utility values for acute myeloid leukemia

Por Forsythe, Anna, Brandt, Patricia S, Dolph, Mike, Patel, Sachin, Rabe, Adrian Paul J, Tremblay, Gabriel
Publicado no Clinicoecon Outcomes Res (2018)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

Por Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Roy, Anuja, Elliott, Brian, Briggs, Andrew
Publicado no Clinicoecon Outcomes Res (2018)